-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Tempest Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2021 to Q3 2024.
- Tempest Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$5K, a 97.4% increase year-over-year.
- Tempest Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $103K.
- Tempest Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$334K, a 68.8% increase from 2022.
- Tempest Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$1.07M, a 18.8% increase from 2021.
- Tempest Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.32M, a 1562% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)